#1 Clinical Trials Search in Europe

Human Igg1K Monoclonal Antibody Against Tim-3

This article discusses ongoing clinical trials investigating the use of Human IgG1K Monoclonal Antibody Against TIM-3, also known as INCAGN02390, in treating various types of cancer. The trials aim to evaluate the safety and effectiveness of this antibody, either alone or in combination with other therapies, for patients with advanced endometrial cancer and head and neck cancer. These studies represent important steps in developing new immunotherapy options for cancer patients.

Table of Contents

What is INCAGN02390?

INCAGN02390 is a human IgG1k monoclonal antibody that targets a protein called TIM-3 (T cell immunoglobulin and mucin domain-containing protein 3)[1]. It is being developed by Incyte Corporation as a potential new treatment for various types of cancer. This medication is classified as a biological or biotechnological product, which means it is derived from living organisms and designed to interact with specific targets in the body[2].

How does it work?

INCAGN02390 works by targeting and blocking TIM-3, a protein found on the surface of certain immune cells. TIM-3 is known to play a role in suppressing the immune system’s ability to fight cancer. By blocking TIM-3, INCAGN02390 aims to enhance the immune system’s response against cancer cells, potentially leading to better control of tumor growth and spread[1].

What conditions does it treat?

Based on the available clinical trial information, INCAGN02390 is being studied for the treatment of several types of cancer, including:

  • Endometrial cancer: This is cancer that starts in the lining of the uterus (endometrium)[1].
  • Squamous Cell Carcinoma of the Head and Neck (SCCHN): This refers to cancers that develop in the mouth, nose, throat, or other areas of the head and neck[2].

It’s important to note that INCAGN02390 is still in the experimental stage and is not yet approved for general use outside of clinical trials.

Clinical Trials

INCAGN02390 is currently being evaluated in several clinical trials:

  1. Endometrial Cancer Study: This trial is investigating INCAGN02390 in combination with other drugs for patients with advanced or metastatic endometrial cancer who have progressed after platinum-based chemotherapy[1].
  2. Head and Neck Cancer Study: This is a Phase 2 study examining INCAGN02390 in combination with other immunotherapy drugs for the first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck in patients whose tumors are positive for a protein called PD-L1[2].

These trials aim to determine how effective INCAGN02390 is in treating these cancers, either alone or in combination with other drugs, and to assess its safety profile.

Administration

INCAGN02390 is administered as a solution for infusion, which means it is given directly into the bloodstream through a vein (intravenously)[1][2]. The dosage and frequency of administration may vary depending on the specific clinical trial and the patient’s condition.

Potential Side Effects

As INCAGN02390 is still in clinical trials, the full range of potential side effects is not yet known. However, as with other immunotherapy drugs, it may cause side effects related to increased immune system activity. These could potentially include:

  • Fatigue
  • Skin reactions
  • Gastrointestinal issues
  • Immune-related adverse events

It’s important to note that the clinical trials are closely monitoring for any adverse events to ensure patient safety[2].

Conclusion

INCAGN02390 represents a promising new approach in cancer immunotherapy. By targeting TIM-3, it aims to enhance the body’s natural defenses against cancer. While still in the experimental stage, ongoing clinical trials are providing valuable information about its effectiveness and safety in treating endometrial cancer and head and neck cancer. As research progresses, we may learn more about its potential applications in other types of cancer as well.

Aspect Details
Drug Name Human IgG1K Monoclonal Antibody Against TIM-3 (INCAGN02390)
Cancer Types Studied Advanced/metastatic endometrial cancer, Recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN)
Administration Method Intravenous infusion
Study Designs Phase 2 trials, Combination therapy with other immunotherapy drugs
Primary Objectives Evaluate safety and efficacy, Measure tumor response rates, Assess progression-free survival
Key Inclusion Criteria Adults with specific cancer types, Measurable disease, Adequate organ function
Key Exclusion Criteria Active autoimmune diseases, Certain infections (HIV, hepatitis), Recent use of other immunotherapies
Outcome Measures Objective response rate, Duration of response, Overall survival, Safety profile

FAQ

  • What is Human IgG1K Monoclonal Antibody Against TIM-3? Human IgG1K Monoclonal Antibody Against TIM-3, also known as INCAGN02390, is a type of immunotherapy drug. It works by targeting a protein called TIM-3, which is involved in regulating immune responses. By blocking TIM-3, this antibody aims to enhance the body's immune system to fight cancer cells.
  • What types of cancer are being studied with this drug? The clinical trials mentioned in this article are studying the use of Human IgG1K Monoclonal Antibody Against TIM-3 in advanced or metastatic endometrial cancer and recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN).
  • How is the drug administered to patients? The drug is administered as a solution for intravenous infusion, meaning it is given directly into the bloodstream through a vein.
  • Is this drug being used alone or in combination with other treatments? The clinical trials are exploring the use of Human IgG1K Monoclonal Antibody Against TIM-3 both as a monotherapy (used alone) and in combination with other drugs, such as retifanlimab and INCAGN02385, which target different immune checkpoints.
  • What are the main goals of these clinical trials? The main goals of these trials are to evaluate the safety and effectiveness of Human IgG1K Monoclonal Antibody Against TIM-3 in treating specific types of cancer. They aim to measure outcomes such as tumor response rates, progression-free survival, overall survival, and the occurrence of side effects.

Ongoing Clinical Trials on Human Igg1K Monoclonal Antibody Against Tim-3

  • Study of Retifanlimab Alone and in Combination with Drug Therapy for Adults with Advanced or Metastatic Endometrial Cancer Who Have Not Responded to Platinum Chemotherapy

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Greece Italy

  • Study of Retifanlimab, INCAGN02385, and INCAGN02390 for First-Line Treatment in Patients with PD-L1 Positive Recurrent/Metastatic Head and Neck Cancer

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France Greece Italy Portugal Spain

Glossary

  • Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. Monoclonal antibodies are used to treat some types of cancer.
  • TIM-3: T cell immunoglobulin and mucin domain-3, a protein involved in regulating immune responses. It is a target for cancer immunotherapy.
  • Endometrial Cancer: A type of cancer that begins in the lining of the uterus (endometrium).
  • Squamous Cell Carcinoma of the Head and Neck (SCCHN): A type of cancer that begins in the squamous cells lining the mouth, nose, and throat.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Immunotherapy: A type of cancer treatment that helps the immune system fight cancer.
  • RECIST v1.1: Response Evaluation Criteria in Solid Tumors version 1.1, a standard way to measure how well a cancer patient responds to treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.

References

  1. http://clinicaltrials.eu/trial/study-of-retifanlimab-and-drug-combination-for-patients-with-advanced-or-metastatic-endometrial-cancer-after-platinum-based-chemotherapy/
  2. http://clinicaltrials.eu/trial/study-of-retifanlimab-incagn02385-and-incagn02390-for-first-line-treatment-in-patients-with-pd-l1-positive-recurrent-metastatic-head-and-neck-cancer/